The CSL Behring Difference
View product pipeline
- CSL Behring Global Product Portfolio (PDF, 28KB)
CSL Behring is a specialty biotherapeutics company. For more than a century, we
have been serving people around the world who have serious medical conditions.
Biotherapies differ from conventional pharmaceuticals. They are derived from human
blood plasma or are manufactured using recombinant technologies. Conventional pharmaceuticals
generally are derived from chemicals.
CSL Behring develops, manufactures, and markets protein-based therapies in the following areas:
Bleeding Disorders Therapies >
Fluid Replacement Therapies >
Hereditary Angioedema (HAE) Therapies >
Immunoglobulin Therapies >
Pulmonary Therapies >
Wound Healing Therapies >
CSL Behring is proud to serve communities of people who have von Willebrand disease
(VWD), hemophilia, primary immunodeficiency (PID), hereditary Angioedema (HAE),
fibrinogen deficiency, genetic emphysema, and other rare diseases. Our biotherapies
can also prevent hemolytic disease of the newborn, and prevent or stop bleeding
in emergencies or planned surgery.
CSL Behring is passionate about saving lives and about improving the quality of
life for people with rare diseases.
Product availability varies from country to country, depending on registration status.
Please contact your CSL Behring representative for more information.